SuperworthSolventum EPS SOLV
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- $8.18
- Latest quarter, Q2 FY26
- $0.53
- +4% on a year earlier
- Fiscal year 2025
- $8.87
- +221% on the year before
Solventum's earnings per share was $8.18 over the twelve months to Jun 30, 2026, up 277% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.53, up 4% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $8.87 | +221% |
| FY2024 | $2.76 | −65% |
| FY2023 | $7.79 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.53 | +4% | $8.18 | |
| Q1 FY26 | $0.07 | −91% | $8.16 | |
| Q4 FY25 | $0.36 | +100% | $8.87 | |
| Q3 FY25 | $7.22 | +931% | $8.69 | |
| Q2 FY25 | $0.51 | +0% | $2.17 | |
| Q1 FY25 | $0.78 | −43% | $2.17 | |
| Q4 FY24 | $0.18 | −89% | $2.76 | |
| Q3 FY24 | $0.70 | −74% | $4.15 | |
| Q2 FY24 | $0.51 | −73% | $6.11 | |
| Q1 FY24 | $1.37 | −19% | $7.46 | |
| Q4 FY23 | $1.57 | n/a | $7.79 | |
| Q3 FY23 | $2.66 | n/a | n/a |
Against its peers
Companies in Medical - Instruments & Supplies nearest Solventum's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SOLVSolventum | $8.18 | +277% a year |
| PENPenumbra | $4.07 | +8% a year |
| COOCooper Companies | $2.93 | +44% a year |
| ALGNAlign Technology | $5.75 | −3% a year |
| GMEDGlobus Medical | $3.91 | +50% a year |
| PODDInsulet | $5.35 | +64% a year |
| WSTWest Pharmaceutical Services | $7.81 | +17% a year |
| MSAMSA Safety | $8.04 | +15% a year |
| RMDResMed | $10.43 | +10% a year |
| MMSIMerit Medical Systems | $2.42 | +23% a year |
| HAEHaemonetics | $2.04 | −38% a year |
| Peer median | $4.71 |
Where Solventum ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Solventum
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.